We are developing our technology in areas of high unmet medical need in (i) debilitating diseases; (ii) where chronic treatment is required to control disease; (iii) and where localised, non-systemic activity promises to improve safety and tolerability. The company also has a wide range of pioneering molecules as potential candidates for a range of gastrointestinal (GI) and ocular inflammatory conditions.
TopiVert’s most advanced drug candidate is TOP1288 for the treatment of ulcerative colitis (UC) where a Phase 2a POC study with a rectal formulation and a Phase 1 study with an oral formulation are ongoing. In parallel, our lead ophthalmology product, TOP1630 in the treatment of dry eye disease, is currently in a Phase 1/2a proof of concept study in the US. All three studies are due to report in the second half of 2017.